 The ancillary study is a sub-study within START. This is an exploratory investigation of the immune response in peripheral blood after tecemotide L-BLP25 or placebo vaccination. The main objective is to evaluate whether administration of single-shot, low-dose cyclophosphamide followed by tecemotide L-BLP25 vaccinations induces specific immune response in peripheral blood to BLP25 the mucinous glycoprotein 1 MUC1 antigen as well as a modulation of cellular and soluble components of the immune response in subjects with unresectable stage III NSCLC. 